Lexaria Bioscience (LEXX) Change in Account Payables (2010 - 2021)
Lexaria Bioscience's (LEXX) quarterly Change in Account Payables came in at -$5223.0 in Q4 2021, down 118.34% year-on-year from $28481.0 in Q4 2020, and down 233.96% quarter-over-quarter from $3899.0 in Q3 2021.
Lexaria Bioscience (LEXX) Change in Account Payables (2010 - 2021) Analysis & Trends
Lexaria Bioscience has disclosed Change in Account Payables across 12 years of filings, most recently posting -$5223.0 for Q4 2021.
- Change in Account Payables for Q4 2021 came in at -$5223.0, down 118.34% year-over-year; the trailing twelve-month figure through Aug 2022 was -$5223.0 (up 90.23% YoY), and the FY2022 annual result was -$5223.0, up 90.23% from the prior year.
- Change in Account Payables came in at -$5223.0 for Q4 2021 at Lexaria Bioscience, down from $3899.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $119621.0 in Q1 2021 to a low of -$243169.0 in Q2 2017.
- The 5-year median for Change in Account Payables is $1130.5 (2018), against an average of -$16399.6.
- Across the five-year window, Change in Account Payables plunged 2857.33% in 2017 and surged 2259.44% in 2019, its largest moves.
- Lexaria Bioscience's Change in Account Payables stood at -$17672.0 in 2017, then soared by 178.08% to $13799.0 in 2018, then slumped by 178.96% to -$10896.0 in 2019, then jumped by 361.39% to $28481.0 in 2020, then plunged by 118.34% to -$5223.0 in 2021.
- The last three Change in Account Payables figures came in at -$5223.0 (Q4 2021), $3899.0 (Q3 2021), and -$205482.0 (Q2 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -9.42 Mn |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2021 | -5,223.00 |
| Nov 30, 2021 | -5,223.00 |
| Aug 31, 2021 | 3,899.00 |
| Aug 31, 2021 | 3,899.00 |
| May 31, 2021 | -205,482.00 |
| May 31, 2021 | -205,482.00 |
| Feb 28, 2021 | 119,621.00 |
| Feb 28, 2021 | 119,621.00 |
| Nov 30, 2020 | 28,481.00 |
| Nov 30, 2020 | 28,481.00 |
| Aug 31, 2020 | 29,109.00 |
| Aug 31, 2020 | 29,109.00 |
| May 31, 2020 | 27,995.00 |
| May 31, 2020 | 27,995.00 |
| Feb 29, 2020 | -35,600.00 |
| Feb 29, 2020 | -35,600.00 |
| Nov 30, 2019 | -10,896.00 |
| Nov 30, 2019 | -10,896.00 |
| Aug 31, 2019 | 27,101.00 |
| Aug 31, 2019 | 27,101.00 |